Tributyrin

三丁酸甘油酯

Report date: 2026/04/03 20:03:44
NME

Base Information

Drug NameTributyrin
Drug Alias NameNSC-661583
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone deacetylase inhibitorsCell differentiation stimulants
TargetsHistone deacetylase
Therapy Area/IndicationsSolid tumoursDiabetes MellitusLeber Congenital Amaurosis +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesEgypt
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of MichiganGeorge Washington University (The)Ain Shams University
Inactive CompaniesSuzhou UniversityNational Cancer InstituteUniversity Of Maryland, Baltimore
Active IndicationsDiabetes MellitusLeber Congenital AmaurosisParkinson Disease +[4] 
Inactive IndicationsSolid tumoursProstatic NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG